Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

 SANA -Sana Biotechnology, Inc.

Name : Sana Biotechnology, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $0.0000
EPSttm :
finviz dynamic chart for SANA
[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=SANA #%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
[iframe https://api.stockdio.com/visualization/financial/charts/v1/PricesChange?app-key=F086EEE750E14D8D8A456DB88B2D6D8C&symbol=SANA &conditionalVolume=false&allowPeriodChange=false&tooltipsStyle=None&palette=Financial-Light&showBorderAndTitle=false 300 200 ]

Float Short %

27.79

Margin Of Safety %

Put/Call OI Ratio

0.23

EPS Next Q Diff

-0.02

EPS Last/This Y

0.41

EPS This/Next Y

0.01

Price

3.91

Target Price

8.2

Analyst Recom

1.29

Performance Q

105.79

Relative Volume

0.83

Beta

1.91

Ticker: SANA




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04SANA3.180.180.0425540
2025-07-07SANA3.110.170.2725537
2025-07-08SANA3.890.180.2926432
2025-07-09SANA4.040.220.0728099
2025-07-10SANA4.060.220.1129038
2025-07-11SANA4.170.220.0128844
2025-07-14SANA4.210.200.1931018
2025-07-15SANA4.180.210.0531631
2025-07-16SANA4.320.210.1632134
2025-07-17SANA4.450.210.2333242
2025-07-18SANA4.640.220.8734051
2025-07-21SANA4.430.220.0524109
2025-07-22SANA4.880.210.0125364
2025-07-23SANA5.140.210.1025945
2025-07-24SANA5.130.210.5326830
2025-07-25SANA4.940.250.1129184
2025-07-28SANA4.870.260.1230018
2025-07-29SANA4.440.260.5130157
2025-07-30SANA4.350.230.0329275
2025-07-31SANA4.060.230.2229435
2025-08-01SANA3.90.230.0929606
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04SANA3.1937.59.3-0.75
2025-07-07SANA3.1137.531.5-0.75
2025-07-08SANA3.8937.5-21.6-0.75
2025-07-09SANA4.0537.519.0-0.75
2025-07-10SANA4.0637.526.3-0.75
2025-07-11SANA4.1837.520.8-0.75
2025-07-14SANA4.2237.525.0-0.75
2025-07-15SANA4.1837.528.6-0.75
2025-07-16SANA4.3237.520.3-0.75
2025-07-17SANA4.4537.521.6-0.75
2025-07-18SANA4.6437.519.0-0.75
2025-07-21SANA4.4437.534.4-0.75
2025-07-22SANA4.8637.58.9-0.75
2025-07-23SANA5.1437.516.3-0.75
2025-07-24SANA5.1337.527.1-0.75
2025-07-25SANA4.9537.533.3-0.75
2025-07-28SANA4.8637.530.4-0.75
2025-07-29SANA4.4537.543.4-0.75
2025-07-30SANA4.3637.530.6-0.75
2025-07-31SANA4.0637.539.7-0.75
2025-08-01SANA3.9137.533.8-0.75
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04SANA-0.29-6.4634.73
2025-07-07SANA-0.29-6.4634.73
2025-07-08SANA-0.29-6.4634.73
2025-07-09SANA-0.29-6.4634.73
2025-07-10SANA-0.29-6.4634.73
2025-07-11SANA0.00-6.4629.92
2025-07-14SANA0.00-6.4729.92
2025-07-15SANA0.00-6.4729.92
2025-07-16SANA0.00-6.4729.92
2025-07-17SANA0.00-6.4729.92
2025-07-18SANA0.00-6.4729.92
2025-07-21SANA0.00-6.4329.92
2025-07-22SANA0.00-6.4329.92
2025-07-23SANA0.00-6.4329.92
2025-07-24SANA0.00-6.4329.92
2025-07-25SANA0.00-6.4327.79
2025-07-28SANA0.00-6.4227.79
2025-07-29SANA0.00-6.4227.79
2025-07-30SANA0.00-6.4227.79
2025-07-31SANA0.00-6.4227.79
2025-08-01SANA0.00-6.4227.79
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=SANA 589 360 ]

Last Quarter Act. EPS

-0.2

Avg. EPS Est. Current Quarter

-0.2

Avg. EPS Est. Next Quarter

-0.22

Insider Transactions

Institutional Transactions

-6.42

Beta

1.91

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

3

Growth Score

19

Sentiment Score

8

Actual DrawDown %

91.2

Max Drawdown 5-Year %

Target Price

8.2

P/E

Forward P/E

PEG

P/S

P/B

4.22

P/Free Cash Flow

EPS

-0.88

Average EPS Est. Cur. Y​

-0.75

EPS Next Y. (Est.)

-0.74

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.83

Return on Equity vs Sector %

-123.5

Return on Equity vs Industry %

-104.9

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

0.13

EBIT Estimation

33.8
[iframe https://widget.finnhub.io/widgets/recommendation?symbol=SANA 589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=SANA 589 450 ]
Sana Biotechnology, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 194
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
stock quote shares  SANA -Sana Biotechnology, Inc. Stock Price stock today
news today  SANA -Sana Biotechnology, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch  SANA -Sana Biotechnology, Inc. yahoo finance google finance
stock history  SANA -Sana Biotechnology, Inc. invest stock market
stock prices SANA premarket after hours
ticker SANA fair value insiders trading